Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sylvie Lachance"'
Autor:
Dennis Dong Hwan Kim, Gizelle Popradi, Kylie Lepic, Kristjan Paulson, David Allan, Ram Vasudevan Nampoothiri, Sylvie Lachance, Uday Deotare, Jennifer White, Mohamed Elemary, Kareem Jamani, Christina Fraga, Christopher Lemieux, Igor Novitzky-Basso, Arjun Datt Law, Rajat Kumar, Irwin Walker, Kirk R. Schultz
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1426-1444 (2024)
This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a nu
Externí odkaz:
https://doaj.org/article/377e4a7e680a48e3b905fe5521e9a28c
Autor:
Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas Kiss, Sylvie Lachance, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Jean Roy, Imran Ahmad
Publikováno v:
Current Oncology, Vol 29, Iss 8, Pp 5955-5962 (2022)
The purpose of this retrospective study was to study the correlation between donor age (DA) and non-relapse mortality (NRM) and relapse incidence (RI) among patients treated with allogeneic hematopoietic cell transplantation (aHCT) for acute myeloid
Externí odkaz:
https://doaj.org/article/8e30afbb32ae4e7d91ee3b004756ff18
Autor:
Amina Kariminia, Sabine Ivison, Bernard Ng, Jacob Rozmus, Susanna Sung, Avani Varshney, Mahmoud Aljurf, Sylvie Lachance, Irwin Walker, Cindy Toze, Jeff Lipton, Stephanie J. Lee, Jeff Szer, Richard Doocey, Ian Lewis, Clayton Smith, Naeem Chaudhri, Megan K. Levings, Raewyn Broady, Gerald Devins, David Szwajcer, Ronan Foley, Sara Mostafavi, Steven Pavletic, Donna A. Wall, Stephan Couban, Tony Panzarella, Kirk R. Schultz
Publikováno v:
Haematologica, Vol 102, Iss 11 (2017)
Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow. The Canadian Blood and Marrow Transplant Group conducte
Externí odkaz:
https://doaj.org/article/c4b9fa5099614e239a3fd78f424f2a68
Autor:
Olivier Veilleux, Jean-Sébastien Claveau, Habiba Alaoui, Yasmina Serroukh, Imran Ahmad, Jean-Sébastien Delisle, Thomas Kiss, Nadia M. Bambace, Léa Bernard, Sandra Cohen, Guy Sauvageau, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Jean Roy, Sylvie Lachance
Publikováno v:
Transplantation and Cellular Therapy, 28(3), 145-151. Elsevier Inc.
Despite high cure rates with frontline therapy for Hodgkin lymphoma (HL), approximately 30% of patients will relapse or develop primary refractory disease (R/r). Autologous hematopoietic stem cell transplantation (autoHSCT) is the standard of care fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f476caac5cd2ac75bcfbf9b2da262b
https://pure.eur.nl/en/publications/a9e7d328-a57a-44ad-b238-44d3e06f4940
https://pure.eur.nl/en/publications/a9e7d328-a57a-44ad-b238-44d3e06f4940
Autor:
Sylvie Lachance, Alex Bourguignon, Josie-Anne Boisjoly, Philippe Bouchard, Imran Ahmad, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Isabelle Fleury, Thomas Kiss, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Justine Zehr, Miguel Chagnon, Jean Roy
Publikováno v:
Transplantation and Cellular Therapy. 29:34.e1-34.e7
With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best outcomes remains a matter of passionate debate. High-dose chemotherapy f
Autor:
Amina, Kariminia, Sabine, Ivison, Bernard, Ng, Jacob, Rozmus, Susanna, Sung, Avani, Varshney, Mahmoud, Aljurf, Sylvie, Lachance, Irwin, Walker, Cindy, Toze, Jeff, Lipton, Stephanie J, Lee, Jeff, Szer, Richard, Doocey, Ian, Lewis, Clayton, Smith, Naeem, Chaudhri, Megan K, Levings, Raewyn, Broady, Gerald, Devins, David, Szwajcer, Ronan, Foley, Sara, Mostafavi, Steven, Pavletic, Donna A, Wall, Stephan, Couban, Tony, Panzarella, Kirk R, Schultz
Publikováno v:
Haematologica
Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow. The Canadian Blood and Marrow Transplant Group conducte